JP4177208B2 - 静脈内注入用アレンドロナート組成物 - Google Patents
静脈内注入用アレンドロナート組成物 Download PDFInfo
- Publication number
- JP4177208B2 JP4177208B2 JP2003311481A JP2003311481A JP4177208B2 JP 4177208 B2 JP4177208 B2 JP 4177208B2 JP 2003311481 A JP2003311481 A JP 2003311481A JP 2003311481 A JP2003311481 A JP 2003311481A JP 4177208 B2 JP4177208 B2 JP 4177208B2
- Authority
- JP
- Japan
- Prior art keywords
- alendronate
- bone
- composition
- intravenous infusion
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本出願人は、クエン酸ナトリウム/クエン酸緩衝剤が、アレンドロナート静脈内注入用組成物のpHを4〜8の範囲に維持し得、ガラス容器から滲出する溶液中に金属イオンを維持する錯化剤として作用することを見出した。クエン酸塩緩衝剤の低pH維持作用と金属イオン錯化作用とにより、金属イオンによるアレンドロナートの沈降を阻止し、静脈内注入用組成物を貯蔵及びその後の使用に許容され得る粒状物質プロフィールに維持することができる。
アレンドロナートの液体静脈内注入用溶液は、固体経口剤形の嚥下に困難を有する通院患者及び短期間に治療上多量のアレンドロナートを必要とする入院患者に対し、投与が容易であり且つより受け入れやすいという利点を提供する。
エタノール
グリセロール
プロピレングリコール
(安定剤)
EDTA(エチレンジアミン四酢酸)
クエン酸
(抗菌保存剤)
ベンジルアルコール
メチルパラベン
プロピルパラベン
(緩衝剤)
クエン酸/クエン酸ナトリウム
酒石酸水素カリウム
酒石酸水素ナトリウム
酢酸/酢酸ナトリウム
マレイン酸/マレイン酸ナトリウム
フタル酸水素ナトリウム
リン酸/リン酸二水素カリウム
リン酸/リン酸水素二ナトリウム
(張度調節剤)
塩化ナトリウム
マンニトール
デキストロース
アレンドロナート 0.5〜10.0mg
クエン酸ナトリウム 5〜50mg
クエン酸 1〜15mg
塩化ナトリウム 1〜8mg
注射用蒸留水(USP) 1mlまでの量
アレンドロナート 3.33mg
(該酸2.5mgに相当)
塩化ナトリウムUSP試薬結晶 4.91mg
クエン酸ナトリウムUSP 10.3mg
クエン酸USP 2.88mg
注射用蒸留水(USP) 1mlまでの量
pH=5.0
(製造法)
上記量を用い、室温で、前もって調製しておいた、注射用蒸留水(USP、以下の参考文献の1636ページ参照)中の塩化ナトリウム、クエン酸及びクエン酸ナトリウムからなる溶液にアレンドロナートを溶解する。
発熱物質:USP法(上記参考文献の1718ページ)
粒状物質:USP法(上記参考文献の1813ページ)
張度:USP法(上記参考文献の1813ページ)
pH:USP法(上記参考文献の1819ページ)。
上記と同じ比率の、但し0.1mg/mlのアレンドロナートをベースとし、クエン酸ナトリウム及びクエン酸を含まない類似組成物は、30℃で1年間放置すると沈降物を形成する。
Claims (4)
- 静脈内投与用の医薬上許容し得る担体及び組成物のpHを4〜8の範囲に維持するに十分な量の緩衝剤中の医薬上有効量のアレンドロナートを含む、ヒト血液と等張である医薬組成物であり、前記緩衝剤が、クエン酸ナトリウム/クエン酸であり、且つ、0.5〜50:1のモル比の緩衝剤:アレンドロナートの量で存在する、前記医薬組成物。
- 前記アレンドロナートが組成物1ml当り0.5〜10mgの量で存在する、請求項1に記載の医薬組成物。
- 前記医薬上許容し得る担体が水である、請求項1に記載の医薬組成物。
- 前記pHが4〜6の範囲である、請求項1に記載の医薬組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/296,192 US5780455A (en) | 1994-08-24 | 1994-08-24 | Intravenous alendronate formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50823396A Division JP3962429B2 (ja) | 1994-08-24 | 1995-08-21 | 静脈内注入用アレンドロナート組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004075690A JP2004075690A (ja) | 2004-03-11 |
JP4177208B2 true JP4177208B2 (ja) | 2008-11-05 |
Family
ID=23140992
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50823396A Expired - Fee Related JP3962429B2 (ja) | 1994-08-24 | 1995-08-21 | 静脈内注入用アレンドロナート組成物 |
JP2003311481A Expired - Fee Related JP4177208B2 (ja) | 1994-08-24 | 2003-09-03 | 静脈内注入用アレンドロナート組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50823396A Expired - Fee Related JP3962429B2 (ja) | 1994-08-24 | 1995-08-21 | 静脈内注入用アレンドロナート組成物 |
Country Status (10)
Country | Link |
---|---|
US (3) | US5780455A (ja) |
EP (1) | EP0777484B1 (ja) |
JP (2) | JP3962429B2 (ja) |
AT (1) | ATE262909T1 (ja) |
AU (1) | AU698411B2 (ja) |
CA (1) | CA2197210C (ja) |
DE (1) | DE69532810T2 (ja) |
ES (1) | ES2216017T3 (ja) |
PT (1) | PT777484E (ja) |
WO (1) | WO1996005842A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0641325B1 (en) * | 1992-05-21 | 2001-03-07 | Monsanto Company | Retroviral protease inhibitors |
US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
EP1007054A4 (en) * | 1996-10-04 | 2000-07-19 | Merck & Co Inc | LIQUID ALENDRONATE FORMULATIONS |
US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US5994329A (en) | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US6432932B1 (en) | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US6331533B1 (en) | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
US6794536B1 (en) | 1998-12-10 | 2004-09-21 | Aesqen, Inc. | Method for preparation of disodium pamidronate |
US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
EP1256582A1 (en) * | 2000-02-09 | 2002-11-13 | Hokuriku Seiyaku Co., Ltd. | 1h-imidazopyridine derivatives |
CN1180846C (zh) * | 2000-05-05 | 2004-12-22 | 霍夫曼-拉罗奇有限公司 | 含有双膦酸或其盐的,用于皮下给药的凝胶体状药物组合物 |
CA2421652A1 (en) * | 2000-09-14 | 2002-03-21 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
EP1671638A1 (en) * | 2000-09-18 | 2006-06-21 | F H Faulding & Co. Limited | Disphosphonate solutions |
US8721625B2 (en) * | 2001-01-26 | 2014-05-13 | Cook Medical Technologies Llc | Endovascular medical device with plurality of wires |
CA2347330C (en) * | 2001-05-10 | 2002-03-12 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
AT502590A1 (de) * | 2001-09-27 | 2007-04-15 | Oekopharm Forschungs Und Entwi | Basenhältige mikronährstoffmischung |
EP1494683A1 (en) * | 2002-04-05 | 2005-01-12 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
WO2006019843A1 (en) * | 2004-07-15 | 2006-02-23 | Nanobac Life Sciences | Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
US20060204567A1 (en) * | 2005-03-08 | 2006-09-14 | Jiang Hu | Potato proteinase inhibitor II exhibits activity in elevating fasting plasma cholecystokinin concentrations |
US7605148B2 (en) * | 2007-04-16 | 2009-10-20 | Aurobindo Pharma Ltd. | Aqueous oral solution of bisphosphonic acid |
US20100286038A1 (en) * | 2007-09-21 | 2010-11-11 | Valentyn Antochshuk | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
CA2812158A1 (en) * | 2009-09-16 | 2011-03-24 | Mount Sinai School Of Medecine | Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis |
EP2363111A1 (en) * | 2010-03-01 | 2011-09-07 | Combino Pharm, S.L. | Stable pharmaceutical composition comprising bisphosphonate |
US9682090B2 (en) | 2014-11-14 | 2017-06-20 | University Of Washington | Methods for treating and preventing prostate cancer bone metastases |
US20240091181A1 (en) * | 2020-12-29 | 2024-03-21 | Next Science IP Holdings Pty Ltd | Cancer treatment composition and method |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06700B2 (ja) * | 1986-03-27 | 1994-01-05 | 旭化成工業株式会社 | 安定な水性液剤 |
DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
JP2617508B2 (ja) * | 1988-02-05 | 1997-06-04 | エーザイ株式会社 | 安定なジフェンヒドラミン含有水溶液 |
US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
JP2974722B2 (ja) * | 1990-04-03 | 1999-11-10 | 帝国臓器製薬株式会社 | カルシトニン注射液 |
US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
CA2151240A1 (en) * | 1992-12-23 | 1994-07-07 | Donna T. Whiteford | Biophosphonate/estrogen therapy for treating and preventing bone loss |
US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
-
1994
- 1994-08-24 US US08/296,192 patent/US5780455A/en not_active Expired - Fee Related
-
1995
- 1995-08-21 CA CA002197210A patent/CA2197210C/en not_active Expired - Fee Related
- 1995-08-21 AU AU33320/95A patent/AU698411B2/en not_active Ceased
- 1995-08-21 EP EP95929625A patent/EP0777484B1/en not_active Expired - Lifetime
- 1995-08-21 JP JP50823396A patent/JP3962429B2/ja not_active Expired - Fee Related
- 1995-08-21 ES ES95929625T patent/ES2216017T3/es not_active Expired - Lifetime
- 1995-08-21 AT AT95929625T patent/ATE262909T1/de not_active IP Right Cessation
- 1995-08-21 PT PT95929625T patent/PT777484E/pt unknown
- 1995-08-21 WO PCT/US1995/010583 patent/WO1996005842A1/en active IP Right Grant
- 1995-08-21 DE DE69532810T patent/DE69532810T2/de not_active Expired - Lifetime
-
1998
- 1998-03-02 US US09/033,015 patent/US5843924A/en not_active Expired - Fee Related
- 1998-05-05 US US09/072,602 patent/US5914323A/en not_active Expired - Fee Related
-
2003
- 2003-09-03 JP JP2003311481A patent/JP4177208B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2197210A1 (en) | 1996-02-29 |
PT777484E (pt) | 2004-06-30 |
ES2216017T3 (es) | 2004-10-16 |
DE69532810D1 (de) | 2004-05-06 |
DE69532810T2 (de) | 2005-02-17 |
EP0777484A4 (en) | 1998-08-05 |
EP0777484A1 (en) | 1997-06-11 |
CA2197210C (en) | 2008-02-19 |
JP2004075690A (ja) | 2004-03-11 |
AU3332095A (en) | 1996-03-14 |
US5914323A (en) | 1999-06-22 |
JPH10504574A (ja) | 1998-05-06 |
EP0777484B1 (en) | 2004-03-31 |
JP3962429B2 (ja) | 2007-08-22 |
US5843924A (en) | 1998-12-01 |
AU698411B2 (en) | 1998-10-29 |
US5780455A (en) | 1998-07-14 |
WO1996005842A1 (en) | 1996-02-29 |
ATE262909T1 (de) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4177208B2 (ja) | 静脈内注入用アレンドロナート組成物 | |
EP0759757B1 (en) | Oral liquid alendronate formulations | |
KR101202649B1 (ko) | 소듐 디클로페낙 및 β-시클로덱스트린을 포함하는 주사용약학 조성물 | |
EP1286665B1 (en) | Treatment regimen of intravenous zoledronate for the treatment of bone metabolism diseases | |
US4853416A (en) | Solutions of pentamidine | |
US8324189B2 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
KR100385697B1 (ko) | 올파드로네이트를포함하는골체량동화성조성물 | |
US6436913B1 (en) | Use of estramustine phosphate in the treatment of bone metastasis | |
CA2445584A1 (en) | Injectable pamidronate disodium | |
AU719771B2 (en) | Intravenous alendronate formulations | |
Kothari et al. | Reduction of gastric acid secretion on a low-salt diet and furosemide. | |
US20040014729A1 (en) | Use of estramustine phosphate in the treatment of bone metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070807 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080509 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080623 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080812 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080821 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110829 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |